Reuters: IPOX® CEO Josef Schuster Comments on Lumexa Imaging's IPO and Market Trends

In a recent Reuters article, IPOX® CEO Josef Schuster discussed the current IPO market dynamics following Lumexa Imaging's successful $462.5 million initial public offering.

Lumexa Imaging, a leading U.S. diagnostic imaging services provider backed by Welsh, Carson, Anderson & Stowe, priced its shares at $18.50, valuing the company at $1.75 billion. The article highlights that the U.S. IPO market is entering the final stretch of the year with renewed activity, as companies leverage a rebound in equities to go public before 2026.

Dr. Schuster provided analysis on investor sentiment, noting a clear divergence in risk appetite. He emphasized that while the market is open to high-quality, "right" deals like Lumexa, investors remain cautious regarding sectors that have historically underperformed post-IPO.

"Risk appetite is there for the right deal. However, it does not currently extend to sectors which have shown particularly poor post-IPO returns recently, including the mostly VC-backed IPOs in the crypto, AI and fintech space coming out of Silicon Valley."

Read the full article by Arasu Kannagi Basil on Reuters: Welsh Carson-backed Lumexa Imaging raises $463 million in US IPO